Targeting CBLB as a potential therapeutic approach for disseminated candidiasis

Y. Xiao, J. Tang, H. Guo, Y. Zhao, R. Tang, S. Ouyang, Q. Zeng, C.A. Rappleye, M.V.S. Rajaram, L.S. Schlesinger, L. Tao, G.D. Brown, Wallace Y. Langdon, B.T. Li, J. Zhang

    Research output: Contribution to journalArticle

    26 Citations (Scopus)

    Abstract

    © 2016 Nature America, Inc. All rights reserved.Disseminated candidiasis has become one of the leading causes of hospital-acquired blood stream infections with high mobility and mortality. However, the molecular basis of host defense against disseminated candidiasis remains elusive, and treatment options are limited. Here we report that the E3 ubiquitin ligase CBLB directs polyubiquitination of dectin-1 and dectin-2, two key pattern-recognition receptors for sensing Candida albicans, and their downstream kinase SYK, thus inhibiting dectin-1- and dectin-2-mediated innate immune responses. CBLB deficiency or inactivation protects mice from systemic infection with a lethal dose of C. albicans, and deficiency of dectin-1, dectin-2, or both in Cblb-/- mice abrogates this protection. Notably, silencing the Cblb gene in vivo protects mice from lethal systemic C. albicans infection. Our data reveal that CBLB is crucial for homeostatic control of innate immune responses mediated by dectin-1 and dectin-2. Our data also indicate that CBLB represents a potential therapeutic target for protection from disseminated candidiasis.
    Original languageEnglish
    Pages (from-to)906-914
    Number of pages9
    JournalNature Medicine
    Volume22
    Issue number8
    DOIs
    Publication statusPublished - 2016

    Fingerprint

    Candidiasis
    Candida albicans
    Innate Immunity
    Pattern Recognition Receptors
    Ubiquitin-Protein Ligases
    Candida
    Gene Silencing
    Therapeutics
    Infection
    Blood
    Phosphotransferases
    Genes
    Mortality
    dectin 1
    mouse dectin-2

    Cite this

    Xiao, Y., Tang, J., Guo, H., Zhao, Y., Tang, R., Ouyang, S., ... Zhang, J. (2016). Targeting CBLB as a potential therapeutic approach for disseminated candidiasis. Nature Medicine, 22(8), 906-914. https://doi.org/10.1038/nm.4141
    Xiao, Y. ; Tang, J. ; Guo, H. ; Zhao, Y. ; Tang, R. ; Ouyang, S. ; Zeng, Q. ; Rappleye, C.A. ; Rajaram, M.V.S. ; Schlesinger, L.S. ; Tao, L. ; Brown, G.D. ; Langdon, Wallace Y. ; Li, B.T. ; Zhang, J. / Targeting CBLB as a potential therapeutic approach for disseminated candidiasis. In: Nature Medicine. 2016 ; Vol. 22, No. 8. pp. 906-914.
    @article{5975b8054c544a9e9125110fa00bf4e4,
    title = "Targeting CBLB as a potential therapeutic approach for disseminated candidiasis",
    abstract = "{\circledC} 2016 Nature America, Inc. All rights reserved.Disseminated candidiasis has become one of the leading causes of hospital-acquired blood stream infections with high mobility and mortality. However, the molecular basis of host defense against disseminated candidiasis remains elusive, and treatment options are limited. Here we report that the E3 ubiquitin ligase CBLB directs polyubiquitination of dectin-1 and dectin-2, two key pattern-recognition receptors for sensing Candida albicans, and their downstream kinase SYK, thus inhibiting dectin-1- and dectin-2-mediated innate immune responses. CBLB deficiency or inactivation protects mice from systemic infection with a lethal dose of C. albicans, and deficiency of dectin-1, dectin-2, or both in Cblb-/- mice abrogates this protection. Notably, silencing the Cblb gene in vivo protects mice from lethal systemic C. albicans infection. Our data reveal that CBLB is crucial for homeostatic control of innate immune responses mediated by dectin-1 and dectin-2. Our data also indicate that CBLB represents a potential therapeutic target for protection from disseminated candidiasis.",
    author = "Y. Xiao and J. Tang and H. Guo and Y. Zhao and R. Tang and S. Ouyang and Q. Zeng and C.A. Rappleye and M.V.S. Rajaram and L.S. Schlesinger and L. Tao and G.D. Brown and Langdon, {Wallace Y.} and B.T. Li and J. Zhang",
    year = "2016",
    doi = "10.1038/nm.4141",
    language = "English",
    volume = "22",
    pages = "906--914",
    journal = "Nature Medicine",
    issn = "1078-8956",
    publisher = "Nature Publishing Group - Macmillan Publishers",
    number = "8",

    }

    Xiao, Y, Tang, J, Guo, H, Zhao, Y, Tang, R, Ouyang, S, Zeng, Q, Rappleye, CA, Rajaram, MVS, Schlesinger, LS, Tao, L, Brown, GD, Langdon, WY, Li, BT & Zhang, J 2016, 'Targeting CBLB as a potential therapeutic approach for disseminated candidiasis' Nature Medicine, vol. 22, no. 8, pp. 906-914. https://doi.org/10.1038/nm.4141

    Targeting CBLB as a potential therapeutic approach for disseminated candidiasis. / Xiao, Y.; Tang, J.; Guo, H.; Zhao, Y.; Tang, R.; Ouyang, S.; Zeng, Q.; Rappleye, C.A.; Rajaram, M.V.S.; Schlesinger, L.S.; Tao, L.; Brown, G.D.; Langdon, Wallace Y.; Li, B.T.; Zhang, J.

    In: Nature Medicine, Vol. 22, No. 8, 2016, p. 906-914.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Targeting CBLB as a potential therapeutic approach for disseminated candidiasis

    AU - Xiao, Y.

    AU - Tang, J.

    AU - Guo, H.

    AU - Zhao, Y.

    AU - Tang, R.

    AU - Ouyang, S.

    AU - Zeng, Q.

    AU - Rappleye, C.A.

    AU - Rajaram, M.V.S.

    AU - Schlesinger, L.S.

    AU - Tao, L.

    AU - Brown, G.D.

    AU - Langdon, Wallace Y.

    AU - Li, B.T.

    AU - Zhang, J.

    PY - 2016

    Y1 - 2016

    N2 - © 2016 Nature America, Inc. All rights reserved.Disseminated candidiasis has become one of the leading causes of hospital-acquired blood stream infections with high mobility and mortality. However, the molecular basis of host defense against disseminated candidiasis remains elusive, and treatment options are limited. Here we report that the E3 ubiquitin ligase CBLB directs polyubiquitination of dectin-1 and dectin-2, two key pattern-recognition receptors for sensing Candida albicans, and their downstream kinase SYK, thus inhibiting dectin-1- and dectin-2-mediated innate immune responses. CBLB deficiency or inactivation protects mice from systemic infection with a lethal dose of C. albicans, and deficiency of dectin-1, dectin-2, or both in Cblb-/- mice abrogates this protection. Notably, silencing the Cblb gene in vivo protects mice from lethal systemic C. albicans infection. Our data reveal that CBLB is crucial for homeostatic control of innate immune responses mediated by dectin-1 and dectin-2. Our data also indicate that CBLB represents a potential therapeutic target for protection from disseminated candidiasis.

    AB - © 2016 Nature America, Inc. All rights reserved.Disseminated candidiasis has become one of the leading causes of hospital-acquired blood stream infections with high mobility and mortality. However, the molecular basis of host defense against disseminated candidiasis remains elusive, and treatment options are limited. Here we report that the E3 ubiquitin ligase CBLB directs polyubiquitination of dectin-1 and dectin-2, two key pattern-recognition receptors for sensing Candida albicans, and their downstream kinase SYK, thus inhibiting dectin-1- and dectin-2-mediated innate immune responses. CBLB deficiency or inactivation protects mice from systemic infection with a lethal dose of C. albicans, and deficiency of dectin-1, dectin-2, or both in Cblb-/- mice abrogates this protection. Notably, silencing the Cblb gene in vivo protects mice from lethal systemic C. albicans infection. Our data reveal that CBLB is crucial for homeostatic control of innate immune responses mediated by dectin-1 and dectin-2. Our data also indicate that CBLB represents a potential therapeutic target for protection from disseminated candidiasis.

    U2 - 10.1038/nm.4141

    DO - 10.1038/nm.4141

    M3 - Article

    VL - 22

    SP - 906

    EP - 914

    JO - Nature Medicine

    JF - Nature Medicine

    SN - 1078-8956

    IS - 8

    ER -